这项研究调查了免疫检查点抑制剂（ICIs）联合化疗作为一种有前景的恶性肿瘤治疗方法的潜力。本报告重点关注一位接受化疗和 ICI 后出现药物性肝损伤 (DILI) 的患者。一名 63 岁非小细胞肺腺癌 (NSCLC) 患者最初接受 γ 刀治疗，随后接受贝伐单抗和卡瑞利珠单抗联合化疗。由于肝脏异常，化疗和ICIs均在第21天停止。甲泼尼龙治疗后一个月内，患者肝功能得到改善。随后，患者接受卡铂、培美曲塞和贝伐单抗治疗，没有出现并发症。这一发现支持了 DILI 可能是由 ICI 引发的观点。本病例系列详细介绍了因使用 ICI 和培美曲塞/卡铂而导致 DILI 的复杂情况。病理结果和临床表现的一致性强烈表明 ICI 诱发了 DILI，类固醇治疗的明确反应进一步支持了这一点。该信息对临床医生很重要，因为它强调了密切监测肝功能并意识到与 ICI 相关的潜在不良反应的重要性。这些见解有助于更有效的患者护理。版权所有 © 2024 Lou、Wang、Yuan、Zhao、Feng、Ding、Lin、Liu、Wang、Chi 和 Wang。

This study investigated the potential of immune checkpoint inhibitors (ICIs) combined with chemotherapy as a promising treatment approach for malignancies. This report focuses on a patient with drug-induced liver injury (DILI) following the administration of chemotherapy and ICIs. A 63-year-old patient with non-small cell lung adenocarcinoma (NSCLC) initially underwent γ-knife treatment and subsequently received a combination of chemotherapy comprising bevacizumab and camrelizumab. Due to liver abnormalities, both chemotherapy and ICIs were stopped on day 21. The patient's liver function improved within a month after methylprednisolone treatment. Subsequently, the patient received carboplatin, pemetrexed, and bevacizumab without complications. This finding supported the notion that DILI was likely triggered by the ICI. This case series details a complex instance of DILI resulting from the use of ICIs and pemetrexed/carboplatin. The alignment of the pathological findings and clinical presentation strongly suggested ICI-induced DILI, which was further supported by the definitive response to steroid treatment. This information is important for clinicians, as it emphasizes the importance of closely monitoring liver function and being aware of potential adverse effects associated with ICIs. Such insights contribute to more effective patient care.Copyright © 2024 Lou, Wang, Yuan, Zhao, Feng, Ding, Lin, Liu, Wang, Chi and Wang.